Autres langues Syros Pharmaceuticals, Inc.

Actions

SYRS

US87184Q2066

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 15:35:17 30/04/2026			Varia. 5j.	Varia. 1 janv.
0,000200 ^USD	-.--%		+100,00%	-42,86%

28/02/25	Syros Pharmaceuticals se retire du Nasdaq et désenregistre ses actions ordinaires	MT
28/02/25	Syros Pharmaceuticals, Inc. annonce la cessation des fonctions de Gerald Quirk en tant que directeur général, à compter du 1er mars 2025	CI

Autres langues

24/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index
19/03/25	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index
28/02/25	Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares
28/02/25	Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025
28/02/25	Syros Pharmaceuticals, Inc. Announces Management Changes
28/02/25	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
23/12/24	Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) dropped from S&P Global BMI Index
18/11/24	Syros Pharmaceuticals : Management Change/Compensation Form 8 K
13/11/24	Syros Pharmaceuticals : Announces Topline Data from SELECT MDS 1 Phase 3 Trial of Tamibarotene in Higher Risk Myelodysplastic Syndrome with RARA Gene Overexpression Form 8 K
13/11/24	Syros Pharmaceuticals, Inc. Announces Event of Default Occurred Under the Loan and Security Agreement with Oxford Finance LLC
12/11/24	Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
12/11/24	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
01/11/24	Syros Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides a Business Update
31/10/24	Syros Pharmaceuticals : Release Q3 2024
31/10/24	Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
31/10/24	Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
24/10/24	Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
23/09/24	Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) added to S&P Global BMI Index
27/08/24	Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
13/08/24	Sector Update: Health Care Stocks Rise Late Afternoon
13/08/24	Top Midday Decliners
13/08/24	Wholesale Inflation Cooled in July as US Equity Futures Rise Pre-Bell
13/08/24	Top Premarket Decliners
12/08/24	Syros Pharmaceuticals Ends Trial of Prospective Acute Myeloid Leukemia Treatment -- Shares Plunge
12/08/24	Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial